BIOMARKERS IN MEDICINE:
Biomarkers in Medicine is a comprehensive guide to understanding the current and future status of biomarkers. The book features 27 chapters focusing on disease biomarkers for diseases such as cancer, neurodegenerative diseases, cardiac diseases, metabolic conditions and much more. This book supplies...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
[S.l.] :
BENTHAM SCIENCE PUBLISHER,
2022.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Biomarkers in Medicine is a comprehensive guide to understanding the current and future status of biomarkers. The book features 27 chapters focusing on disease biomarkers for diseases such as cancer, neurodegenerative diseases, cardiac diseases, metabolic conditions and much more. This book supplies readers with the unique insight of experts in multiple specialties in medicine and life sciences who have extensive experience in diagnostics and clinical laboratories. The book includes case studies and practical examples from different classes of biomarkers on different platforms, including new data for biomarkers in different therapeutic indications. In addition to presenting biomarker information, each chapter covers the relevant pathology and also emphasizes on preclinical and clinical manifestation of the disease process. Clinicians managing patients or clinical trials, clinical researchers, clinical laboratories, diagnostic companies, regulatory agencies, medical school graduate students, academic students, and the general public involved in healthcare delivery will all benefit from information presented in this book. |
| Beschreibung: | 1 online resource |
| ISBN: | 9815040464 9789815040463 |
Internformat
MARC
| LEADER | 00000cam a2200000 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1344187148 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m d | ||
| 007 | cr ||||||||||| | ||
| 008 | 220912s2022 xx o ||| 0 eng d | ||
| 040 | |a YDX |b eng |c YDX |d SFB |d OCLCO |d N$T |d OCLCO |d OCLCQ | ||
| 020 | |a 9815040464 |q (electronic bk.) | ||
| 020 | |a 9789815040463 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1344187148 | ||
| 050 | 4 | |a R856 |b .B566 2022 | |
| 082 | 7 | |a 610.28 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a PINAR, ATUKEREN; HAFIZE, UZUN. | |
| 245 | 1 | 0 | |a BIOMARKERS IN MEDICINE |h [electronic resource]. |
| 260 | |a [S.l.] : |b BENTHAM SCIENCE PUBLISHER, |c 2022. | ||
| 300 | |a 1 online resource | ||
| 505 | 0 | |a Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- New Biomarkers and Immunotherapy Decision -- Abdurrahman Yigit1, Berkay Kuscu2, Ali Kirik2, Ruhsen Ozcaglayan2 and Cigdem Usul Afsar3,* -- NEW BIOMARKERS AND IMMUNOTHERAPY DECISION -- Principles of Cancer İmmunotherapy -- Tumor Immunology -- Therapeutic Approaches -- Immune Checkpoint Inhibitors (ICI) -- THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY -- Immunotherapy Toxicity -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Gynecologic Tumors -- Selim Afsar1,* -- INTRODUCTION -- Ovarian and Fallopian Tube Cancers -- Carbohydrate Antigen 125 (CA125) -- Screening -- Prediction Models -- Prognosis -- Recurrence -- Human Epididymis Protein 4 (HE4) -- Diagnosis -- Prognosis -- Risk of Ovarian Malignancy Algorithm (ROMA) -- Circulating Cell-Free DNA (cfDNA) -- DNA Methylation -- Metabolites -- MicroRNAs -- Carcinoembryonic Antigen (CEA) -- Alpha-Fetoprotein (AFP) -- Inhibin B -- Human Chorionic Gonadotropin (hCG) -- Kallikreins -- Other Markers -- Uterine Cancer -- CA125 -- HE4 -- Genomic Classification -- Other Markers -- Cervical Cancer -- Squamous Cell Carcinoma Antigen (SCC-Ag) -- Other Markers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Urological Cancers -- Bulent Onal1,*, Mehmet Hamza Gultekin1, Muhammed Fatih Simsekoglu1, Berin Selcuk1 and Ahmet Gurbuz1 -- BIOMARKERS IN BLADDER CANCER -- Blood-based Biomarkers -- Tumor Cells -- CD8 Count and Immune Cells -- Matrix Metalloproteinase -- Epigenetic Markers -- Tissue-based Biomarkers -- Cell Cycle-based Markers -- Transmembrane- and Signaling-based Markers -- PDL/PDL1 -- mTOR -- MDR1 -- Human Epidermal Growth Factor Receptor 2 (HER2). | |
| 505 | 8 | |a Anaplastic Thyroid Cancer -- SEROLOGICAL BIOMARKERS -- Thyroglobulin -- Anti-thyroglobulin Antibodies -- Calcitonin and Procalcitonin -- Carcinoembryonic Antigen -- Other Peptides -- LIQUID BIOPSY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives -- Sinem Durmus1,*, Remise Gelisgen1 and Hafize Uzun2 -- INTRODUCTION -- DNA METHYLATION AND REGULATION MECHANISM -- DNA Methylation in Cancer -- Regional Hypermethylation -- Global Hypomethylation -- DNA Methylation Biomarkers in Cancer -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Tissue Based Biomarkers -- DNA Alterations: Polymorphisms -- Gene Expression -- MicroRNA (miRNA) -- Blood Based Biomarkers -- cfDNA and ctDNA -- cfmRNA and hTERT -- cfmiRNA -- CIRCULATING PROTEINS/PEPTIDES -- OTHER PREDICTIVE BIOMARKERS -- Thymidylate Synthase (TS) -- Epidermal Growth Factor Receptor (EGFR) -- Cyclooxygenase 2 (COX-2) -- Bax/bcl-2 -- P21 -- Ki-67 -- CEA -- ctDNA -- Circulating Tumour Cells (CTC) -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERANCES -- Circulating Biomarkers in the Management of Breast Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Carcinoembryonic Antigen (CEA) -- MUC-1 -- HER-2 -- Cytokeratins (CK) -- Specific Classes of Circulatory Biomarkers -- Proteins -- Autoantibodies -- Circulating Tumour Cells (CTC) -- Exosomes -- MicroRNA (miRNA) -- Circulating Cell-Free DNA (cfDNA). | |
| 505 | 8 | |a BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER -- MONITORING RESPONSE TO THERAPY AND SURVEILLANCE -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Biomarkers for Hematologic Malignancies -- Nurgül Özgür Yurttaş1 and Ahmet Emre Eşkazan1,* -- INTRODUCTION -- BIOMARKERS IN MYELOID NEOPLASMS -- Acute Myeloid Leukemia -- CYTOGENETIC CLASSIFICATION OF AML -- MRD IN AML -- Myelodysplastic Syndrome -- CHROMOSOMAL ABNORMALITIES IN MDS -- Deletions of Chromosome 5 -- Monosomy 7 and Deletions of Chromosome 7 -- Diagnosis and Classification -- 5q-syndrome/MDS with an Isolated del(5q) -- Role of Cytogenetics in the Prognosis of MDS -- GENETIC MUTATIONS IN MDS -- Myeloproliferative Neoplasms -- Mutations in PV, ET, and PMF -- BIOMARKERS IN CHRONIC MYELOID LEUKEMIA -- Prognostic Factors at the Time of Diagnosis -- Use of the Mutational Analysis in CML -- Identification of Molecular Markers of Progression -- BIOMARKERS IN LYMPHOID NEOPLASMS -- BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA -- CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA -- B-ALL/LBL with Recurrent Genetic Abnormalities -- T-ALL/LBL -- Cytogenetic Abnormalities in T-ALL/LBL -- Molecular Abnormalities in T-ALL/LBL -- EARLY T-CELL PRECURSOR ALL/LBL -- MRD IN ALL -- BIOMARKERS IN LYMPHOMAS -- Biomarkers of Genetic Changes -- B-Cell Lymphoma 6 (BCL6) -- Tumor Protein 53 (TP53) -- V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) -- B-Cell Lymphoma 2 (BCL2) -- Myeloid Differentiation Primary Response 88 (MYD88) -- Other Genetic Biomarkers in B-Cell Lymphomas -- Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL) -- Biomarkers Related to Epigenetic Changes -- Other Epigenetic Gene Features -- MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas. | |
| 505 | 8 | |a Other MicroRNAs and MicroRNA-Based Classifiers -- Immunophenotypic Biomarkers -- CD30 -- Bcl-6, Bcl-2, and Myc -- Cyclin D1 and SOX-11 -- TP53 and MDM2 -- Immunophenotypic Biomarkers -- Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma -- Microenvironment-related Biomarkers for Prognosis and Immunotherapy -- BIOMARKERS IN MULTIPLE MYELOMA -- STAGING SYSTEMS -- GENOMIC BIOMARKERS -- Gene Expression Profiling -- NOVEL BIOMARKERS -- Minimal Residual Disease -- Next-Generation Biomarkers in MM -- Immunotherapy-related Biomarkers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Applications of Biomarkers in Cancer Surgery -- Berrin Papila Kundaktepe1,* -- INTRODUCTION -- CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS -- Applications Of Tumor Markers In Colorectal Cancer -- Applications of Tumor Markers in Hepatocellular Carcinoma (HCC) -- Applications of Tumor Markers in Pancreatic Adenocarcinoma -- Applications of Tumor Markers In Breast Cancer -- Circulating Tumor Cells -- ENDOCRINE TUMOR MARKERS -- Immunohistochemical and Circulating Tumor Markers of NETs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- A Pathophysiological Approach To Current Biomarkers -- Aykut Oruc1,* and Gonul Simsek1 -- CARDIAC BIOMARKERS -- Cardiac Troponins -- Troponin Subunits -- Regulatory Function of Troponin -- Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology -- Cardiac Troponins as a Biomarker in Congestive Heart Failure -- Heart-Type Fatty Acid Binding Protein -- Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia -- Glycogen Phosphorylase Isoenzyme BB -- Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology -- Glutathione S-Transferase P1 -- N-Terminal pro-Brain Natriuretic Peptide. | |
| 520 | |a Biomarkers in Medicine is a comprehensive guide to understanding the current and future status of biomarkers. The book features 27 chapters focusing on disease biomarkers for diseases such as cancer, neurodegenerative diseases, cardiac diseases, metabolic conditions and much more. This book supplies readers with the unique insight of experts in multiple specialties in medicine and life sciences who have extensive experience in diagnostics and clinical laboratories. The book includes case studies and practical examples from different classes of biomarkers on different platforms, including new data for biomarkers in different therapeutic indications. In addition to presenting biomarker information, each chapter covers the relevant pathology and also emphasizes on preclinical and clinical manifestation of the disease process. Clinicians managing patients or clinical trials, clinical researchers, clinical laboratories, diagnostic companies, regulatory agencies, medical school graduate students, academic students, and the general public involved in healthcare delivery will all benefit from information presented in this book. | ||
| 650 | 0 | |a Biomedical engineering. |0 http://id.loc.gov/authorities/subjects/sh85014237 | |
| 650 | 0 | |a Radiology. |0 http://id.loc.gov/authorities/subjects/sh85110774 | |
| 650 | 0 | |a Biochemical markers. |0 http://id.loc.gov/authorities/subjects/sh85014122 | |
| 650 | 0 | |a Tumor markers. |0 http://id.loc.gov/authorities/subjects/sh85138551 | |
| 650 | 2 | |a Biomarkers |0 https://id.nlm.nih.gov/mesh/D015415 | |
| 650 | 2 | |a Biomarkers, Tumor |0 https://id.nlm.nih.gov/mesh/D014408 | |
| 650 | 2 | |a Radiology |0 https://id.nlm.nih.gov/mesh/D011871 | |
| 650 | 6 | |a Génie biomédical. | |
| 650 | 6 | |a Radiologie. | |
| 650 | 6 | |a Marqueurs biologiques. | |
| 650 | 6 | |a Marqueurs tumoraux. | |
| 650 | 7 | |a biomedical engineering. |2 aat | |
| 650 | 7 | |a radiology. |2 aat | |
| 653 | |a Biochemical Markers | ||
| 653 | |a Clinical Biochemistry | ||
| 653 | |a Science | ||
| 653 | |a Medical | ||
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3378745 |3 Volltext |
| 936 | |a BATCHLOAD | ||
| 938 | |a YBP Library Services |b YANK |n 303113528 | ||
| 938 | |a EBSCOhost |b EBSC |n 3378745 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1344187148 |
|---|---|
| _version_ | 1816882564864933889 |
| adam_text | |
| any_adam_object | |
| author | PINAR, ATUKEREN; HAFIZE, UZUN |
| author_facet | PINAR, ATUKEREN; HAFIZE, UZUN |
| author_role | |
| author_sort | PINAR, ATUKEREN; HAFIZE, UZUN |
| author_variant | a h u p ahu ahup |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | R856 |
| callnumber-raw | R856 .B566 2022 |
| callnumber-search | R856 .B566 2022 |
| callnumber-sort | R 3856 B566 42022 |
| callnumber-subject | R - General Medicine |
| collection | ZDB-4-EBA |
| contents | Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- New Biomarkers and Immunotherapy Decision -- Abdurrahman Yigit1, Berkay Kuscu2, Ali Kirik2, Ruhsen Ozcaglayan2 and Cigdem Usul Afsar3,* -- NEW BIOMARKERS AND IMMUNOTHERAPY DECISION -- Principles of Cancer İmmunotherapy -- Tumor Immunology -- Therapeutic Approaches -- Immune Checkpoint Inhibitors (ICI) -- THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY -- Immunotherapy Toxicity -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Gynecologic Tumors -- Selim Afsar1,* -- INTRODUCTION -- Ovarian and Fallopian Tube Cancers -- Carbohydrate Antigen 125 (CA125) -- Screening -- Prediction Models -- Prognosis -- Recurrence -- Human Epididymis Protein 4 (HE4) -- Diagnosis -- Prognosis -- Risk of Ovarian Malignancy Algorithm (ROMA) -- Circulating Cell-Free DNA (cfDNA) -- DNA Methylation -- Metabolites -- MicroRNAs -- Carcinoembryonic Antigen (CEA) -- Alpha-Fetoprotein (AFP) -- Inhibin B -- Human Chorionic Gonadotropin (hCG) -- Kallikreins -- Other Markers -- Uterine Cancer -- CA125 -- HE4 -- Genomic Classification -- Other Markers -- Cervical Cancer -- Squamous Cell Carcinoma Antigen (SCC-Ag) -- Other Markers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Urological Cancers -- Bulent Onal1,*, Mehmet Hamza Gultekin1, Muhammed Fatih Simsekoglu1, Berin Selcuk1 and Ahmet Gurbuz1 -- BIOMARKERS IN BLADDER CANCER -- Blood-based Biomarkers -- Tumor Cells -- CD8 Count and Immune Cells -- Matrix Metalloproteinase -- Epigenetic Markers -- Tissue-based Biomarkers -- Cell Cycle-based Markers -- Transmembrane- and Signaling-based Markers -- PDL/PDL1 -- mTOR -- MDR1 -- Human Epidermal Growth Factor Receptor 2 (HER2). Anaplastic Thyroid Cancer -- SEROLOGICAL BIOMARKERS -- Thyroglobulin -- Anti-thyroglobulin Antibodies -- Calcitonin and Procalcitonin -- Carcinoembryonic Antigen -- Other Peptides -- LIQUID BIOPSY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives -- Sinem Durmus1,*, Remise Gelisgen1 and Hafize Uzun2 -- INTRODUCTION -- DNA METHYLATION AND REGULATION MECHANISM -- DNA Methylation in Cancer -- Regional Hypermethylation -- Global Hypomethylation -- DNA Methylation Biomarkers in Cancer -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Tissue Based Biomarkers -- DNA Alterations: Polymorphisms -- Gene Expression -- MicroRNA (miRNA) -- Blood Based Biomarkers -- cfDNA and ctDNA -- cfmRNA and hTERT -- cfmiRNA -- CIRCULATING PROTEINS/PEPTIDES -- OTHER PREDICTIVE BIOMARKERS -- Thymidylate Synthase (TS) -- Epidermal Growth Factor Receptor (EGFR) -- Cyclooxygenase 2 (COX-2) -- Bax/bcl-2 -- P21 -- Ki-67 -- CEA -- ctDNA -- Circulating Tumour Cells (CTC) -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERANCES -- Circulating Biomarkers in the Management of Breast Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Carcinoembryonic Antigen (CEA) -- MUC-1 -- HER-2 -- Cytokeratins (CK) -- Specific Classes of Circulatory Biomarkers -- Proteins -- Autoantibodies -- Circulating Tumour Cells (CTC) -- Exosomes -- MicroRNA (miRNA) -- Circulating Cell-Free DNA (cfDNA). BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER -- MONITORING RESPONSE TO THERAPY AND SURVEILLANCE -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Biomarkers for Hematologic Malignancies -- Nurgül Özgür Yurttaş1 and Ahmet Emre Eşkazan1,* -- INTRODUCTION -- BIOMARKERS IN MYELOID NEOPLASMS -- Acute Myeloid Leukemia -- CYTOGENETIC CLASSIFICATION OF AML -- MRD IN AML -- Myelodysplastic Syndrome -- CHROMOSOMAL ABNORMALITIES IN MDS -- Deletions of Chromosome 5 -- Monosomy 7 and Deletions of Chromosome 7 -- Diagnosis and Classification -- 5q-syndrome/MDS with an Isolated del(5q) -- Role of Cytogenetics in the Prognosis of MDS -- GENETIC MUTATIONS IN MDS -- Myeloproliferative Neoplasms -- Mutations in PV, ET, and PMF -- BIOMARKERS IN CHRONIC MYELOID LEUKEMIA -- Prognostic Factors at the Time of Diagnosis -- Use of the Mutational Analysis in CML -- Identification of Molecular Markers of Progression -- BIOMARKERS IN LYMPHOID NEOPLASMS -- BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA -- CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA -- B-ALL/LBL with Recurrent Genetic Abnormalities -- T-ALL/LBL -- Cytogenetic Abnormalities in T-ALL/LBL -- Molecular Abnormalities in T-ALL/LBL -- EARLY T-CELL PRECURSOR ALL/LBL -- MRD IN ALL -- BIOMARKERS IN LYMPHOMAS -- Biomarkers of Genetic Changes -- B-Cell Lymphoma 6 (BCL6) -- Tumor Protein 53 (TP53) -- V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) -- B-Cell Lymphoma 2 (BCL2) -- Myeloid Differentiation Primary Response 88 (MYD88) -- Other Genetic Biomarkers in B-Cell Lymphomas -- Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL) -- Biomarkers Related to Epigenetic Changes -- Other Epigenetic Gene Features -- MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas. Other MicroRNAs and MicroRNA-Based Classifiers -- Immunophenotypic Biomarkers -- CD30 -- Bcl-6, Bcl-2, and Myc -- Cyclin D1 and SOX-11 -- TP53 and MDM2 -- Immunophenotypic Biomarkers -- Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma -- Microenvironment-related Biomarkers for Prognosis and Immunotherapy -- BIOMARKERS IN MULTIPLE MYELOMA -- STAGING SYSTEMS -- GENOMIC BIOMARKERS -- Gene Expression Profiling -- NOVEL BIOMARKERS -- Minimal Residual Disease -- Next-Generation Biomarkers in MM -- Immunotherapy-related Biomarkers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Applications of Biomarkers in Cancer Surgery -- Berrin Papila Kundaktepe1,* -- INTRODUCTION -- CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS -- Applications Of Tumor Markers In Colorectal Cancer -- Applications of Tumor Markers in Hepatocellular Carcinoma (HCC) -- Applications of Tumor Markers in Pancreatic Adenocarcinoma -- Applications of Tumor Markers In Breast Cancer -- Circulating Tumor Cells -- ENDOCRINE TUMOR MARKERS -- Immunohistochemical and Circulating Tumor Markers of NETs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- A Pathophysiological Approach To Current Biomarkers -- Aykut Oruc1,* and Gonul Simsek1 -- CARDIAC BIOMARKERS -- Cardiac Troponins -- Troponin Subunits -- Regulatory Function of Troponin -- Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology -- Cardiac Troponins as a Biomarker in Congestive Heart Failure -- Heart-Type Fatty Acid Binding Protein -- Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia -- Glycogen Phosphorylase Isoenzyme BB -- Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology -- Glutathione S-Transferase P1 -- N-Terminal pro-Brain Natriuretic Peptide. |
| ctrlnum | (OCoLC)1344187148 |
| dewey-full | 610.28 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 610 - Medicine and health |
| dewey-raw | 610.28 |
| dewey-search | 610.28 |
| dewey-sort | 3610.28 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>10525cam a2200553 4500</leader><controlfield tag="001">ZDB-4-EBA-on1344187148</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">220912s2022 xx o ||| 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">YDX</subfield><subfield code="b">eng</subfield><subfield code="c">YDX</subfield><subfield code="d">SFB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9815040464</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789815040463</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1344187148</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">R856</subfield><subfield code="b">.B566 2022</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">610.28</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">PINAR, ATUKEREN; HAFIZE, UZUN.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">BIOMARKERS IN MEDICINE</subfield><subfield code="h">[electronic resource].</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">[S.l.] :</subfield><subfield code="b">BENTHAM SCIENCE PUBLISHER,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- New Biomarkers and Immunotherapy Decision -- Abdurrahman Yigit1, Berkay Kuscu2, Ali Kirik2, Ruhsen Ozcaglayan2 and Cigdem Usul Afsar3,* -- NEW BIOMARKERS AND IMMUNOTHERAPY DECISION -- Principles of Cancer İmmunotherapy -- Tumor Immunology -- Therapeutic Approaches -- Immune Checkpoint Inhibitors (ICI) -- THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY -- Immunotherapy Toxicity -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Gynecologic Tumors -- Selim Afsar1,* -- INTRODUCTION -- Ovarian and Fallopian Tube Cancers -- Carbohydrate Antigen 125 (CA125) -- Screening -- Prediction Models -- Prognosis -- Recurrence -- Human Epididymis Protein 4 (HE4) -- Diagnosis -- Prognosis -- Risk of Ovarian Malignancy Algorithm (ROMA) -- Circulating Cell-Free DNA (cfDNA) -- DNA Methylation -- Metabolites -- MicroRNAs -- Carcinoembryonic Antigen (CEA) -- Alpha-Fetoprotein (AFP) -- Inhibin B -- Human Chorionic Gonadotropin (hCG) -- Kallikreins -- Other Markers -- Uterine Cancer -- CA125 -- HE4 -- Genomic Classification -- Other Markers -- Cervical Cancer -- Squamous Cell Carcinoma Antigen (SCC-Ag) -- Other Markers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Urological Cancers -- Bulent Onal1,*, Mehmet Hamza Gultekin1, Muhammed Fatih Simsekoglu1, Berin Selcuk1 and Ahmet Gurbuz1 -- BIOMARKERS IN BLADDER CANCER -- Blood-based Biomarkers -- Tumor Cells -- CD8 Count and Immune Cells -- Matrix Metalloproteinase -- Epigenetic Markers -- Tissue-based Biomarkers -- Cell Cycle-based Markers -- Transmembrane- and Signaling-based Markers -- PDL/PDL1 -- mTOR -- MDR1 -- Human Epidermal Growth Factor Receptor 2 (HER2).</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Anaplastic Thyroid Cancer -- SEROLOGICAL BIOMARKERS -- Thyroglobulin -- Anti-thyroglobulin Antibodies -- Calcitonin and Procalcitonin -- Carcinoembryonic Antigen -- Other Peptides -- LIQUID BIOPSY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives -- Sinem Durmus1,*, Remise Gelisgen1 and Hafize Uzun2 -- INTRODUCTION -- DNA METHYLATION AND REGULATION MECHANISM -- DNA Methylation in Cancer -- Regional Hypermethylation -- Global Hypomethylation -- DNA Methylation Biomarkers in Cancer -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Tissue Based Biomarkers -- DNA Alterations: Polymorphisms -- Gene Expression -- MicroRNA (miRNA) -- Blood Based Biomarkers -- cfDNA and ctDNA -- cfmRNA and hTERT -- cfmiRNA -- CIRCULATING PROTEINS/PEPTIDES -- OTHER PREDICTIVE BIOMARKERS -- Thymidylate Synthase (TS) -- Epidermal Growth Factor Receptor (EGFR) -- Cyclooxygenase 2 (COX-2) -- Bax/bcl-2 -- P21 -- Ki-67 -- CEA -- ctDNA -- Circulating Tumour Cells (CTC) -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERANCES -- Circulating Biomarkers in the Management of Breast Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Carcinoembryonic Antigen (CEA) -- MUC-1 -- HER-2 -- Cytokeratins (CK) -- Specific Classes of Circulatory Biomarkers -- Proteins -- Autoantibodies -- Circulating Tumour Cells (CTC) -- Exosomes -- MicroRNA (miRNA) -- Circulating Cell-Free DNA (cfDNA).</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER -- MONITORING RESPONSE TO THERAPY AND SURVEILLANCE -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Biomarkers for Hematologic Malignancies -- Nurgül Özgür Yurttaş1 and Ahmet Emre Eşkazan1,* -- INTRODUCTION -- BIOMARKERS IN MYELOID NEOPLASMS -- Acute Myeloid Leukemia -- CYTOGENETIC CLASSIFICATION OF AML -- MRD IN AML -- Myelodysplastic Syndrome -- CHROMOSOMAL ABNORMALITIES IN MDS -- Deletions of Chromosome 5 -- Monosomy 7 and Deletions of Chromosome 7 -- Diagnosis and Classification -- 5q-syndrome/MDS with an Isolated del(5q) -- Role of Cytogenetics in the Prognosis of MDS -- GENETIC MUTATIONS IN MDS -- Myeloproliferative Neoplasms -- Mutations in PV, ET, and PMF -- BIOMARKERS IN CHRONIC MYELOID LEUKEMIA -- Prognostic Factors at the Time of Diagnosis -- Use of the Mutational Analysis in CML -- Identification of Molecular Markers of Progression -- BIOMARKERS IN LYMPHOID NEOPLASMS -- BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA -- CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA -- B-ALL/LBL with Recurrent Genetic Abnormalities -- T-ALL/LBL -- Cytogenetic Abnormalities in T-ALL/LBL -- Molecular Abnormalities in T-ALL/LBL -- EARLY T-CELL PRECURSOR ALL/LBL -- MRD IN ALL -- BIOMARKERS IN LYMPHOMAS -- Biomarkers of Genetic Changes -- B-Cell Lymphoma 6 (BCL6) -- Tumor Protein 53 (TP53) -- V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) -- B-Cell Lymphoma 2 (BCL2) -- Myeloid Differentiation Primary Response 88 (MYD88) -- Other Genetic Biomarkers in B-Cell Lymphomas -- Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL) -- Biomarkers Related to Epigenetic Changes -- Other Epigenetic Gene Features -- MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Other MicroRNAs and MicroRNA-Based Classifiers -- Immunophenotypic Biomarkers -- CD30 -- Bcl-6, Bcl-2, and Myc -- Cyclin D1 and SOX-11 -- TP53 and MDM2 -- Immunophenotypic Biomarkers -- Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma -- Microenvironment-related Biomarkers for Prognosis and Immunotherapy -- BIOMARKERS IN MULTIPLE MYELOMA -- STAGING SYSTEMS -- GENOMIC BIOMARKERS -- Gene Expression Profiling -- NOVEL BIOMARKERS -- Minimal Residual Disease -- Next-Generation Biomarkers in MM -- Immunotherapy-related Biomarkers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Applications of Biomarkers in Cancer Surgery -- Berrin Papila Kundaktepe1,* -- INTRODUCTION -- CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS -- Applications Of Tumor Markers In Colorectal Cancer -- Applications of Tumor Markers in Hepatocellular Carcinoma (HCC) -- Applications of Tumor Markers in Pancreatic Adenocarcinoma -- Applications of Tumor Markers In Breast Cancer -- Circulating Tumor Cells -- ENDOCRINE TUMOR MARKERS -- Immunohistochemical and Circulating Tumor Markers of NETs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- A Pathophysiological Approach To Current Biomarkers -- Aykut Oruc1,* and Gonul Simsek1 -- CARDIAC BIOMARKERS -- Cardiac Troponins -- Troponin Subunits -- Regulatory Function of Troponin -- Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology -- Cardiac Troponins as a Biomarker in Congestive Heart Failure -- Heart-Type Fatty Acid Binding Protein -- Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia -- Glycogen Phosphorylase Isoenzyme BB -- Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology -- Glutathione S-Transferase P1 -- N-Terminal pro-Brain Natriuretic Peptide.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Biomarkers in Medicine is a comprehensive guide to understanding the current and future status of biomarkers. The book features 27 chapters focusing on disease biomarkers for diseases such as cancer, neurodegenerative diseases, cardiac diseases, metabolic conditions and much more. This book supplies readers with the unique insight of experts in multiple specialties in medicine and life sciences who have extensive experience in diagnostics and clinical laboratories. The book includes case studies and practical examples from different classes of biomarkers on different platforms, including new data for biomarkers in different therapeutic indications. In addition to presenting biomarker information, each chapter covers the relevant pathology and also emphasizes on preclinical and clinical manifestation of the disease process. Clinicians managing patients or clinical trials, clinical researchers, clinical laboratories, diagnostic companies, regulatory agencies, medical school graduate students, academic students, and the general public involved in healthcare delivery will all benefit from information presented in this book.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Biomedical engineering.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85014237</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Radiology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85110774</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Biochemical markers.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85014122</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Tumor markers.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85138551</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Biomarkers</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D015415</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Biomarkers, Tumor</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D014408</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Radiology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D011871</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Génie biomédical.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Radiologie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Marqueurs biologiques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Marqueurs tumoraux.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">biomedical engineering.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">radiology.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Biochemical Markers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Clinical Biochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Science</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Medical</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3378745</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="936" ind1=" " ind2=" "><subfield code="a">BATCHLOAD</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">303113528</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">3378745</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1344187148 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:37Z |
| institution | BVB |
| isbn | 9815040464 9789815040463 |
| language | English |
| oclc_num | 1344187148 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBA |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | BENTHAM SCIENCE PUBLISHER, |
| record_format | marc |
| spelling | PINAR, ATUKEREN; HAFIZE, UZUN. BIOMARKERS IN MEDICINE [electronic resource]. [S.l.] : BENTHAM SCIENCE PUBLISHER, 2022. 1 online resource Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- New Biomarkers and Immunotherapy Decision -- Abdurrahman Yigit1, Berkay Kuscu2, Ali Kirik2, Ruhsen Ozcaglayan2 and Cigdem Usul Afsar3,* -- NEW BIOMARKERS AND IMMUNOTHERAPY DECISION -- Principles of Cancer İmmunotherapy -- Tumor Immunology -- Therapeutic Approaches -- Immune Checkpoint Inhibitors (ICI) -- THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY -- Immunotherapy Toxicity -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Gynecologic Tumors -- Selim Afsar1,* -- INTRODUCTION -- Ovarian and Fallopian Tube Cancers -- Carbohydrate Antigen 125 (CA125) -- Screening -- Prediction Models -- Prognosis -- Recurrence -- Human Epididymis Protein 4 (HE4) -- Diagnosis -- Prognosis -- Risk of Ovarian Malignancy Algorithm (ROMA) -- Circulating Cell-Free DNA (cfDNA) -- DNA Methylation -- Metabolites -- MicroRNAs -- Carcinoembryonic Antigen (CEA) -- Alpha-Fetoprotein (AFP) -- Inhibin B -- Human Chorionic Gonadotropin (hCG) -- Kallikreins -- Other Markers -- Uterine Cancer -- CA125 -- HE4 -- Genomic Classification -- Other Markers -- Cervical Cancer -- Squamous Cell Carcinoma Antigen (SCC-Ag) -- Other Markers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Urological Cancers -- Bulent Onal1,*, Mehmet Hamza Gultekin1, Muhammed Fatih Simsekoglu1, Berin Selcuk1 and Ahmet Gurbuz1 -- BIOMARKERS IN BLADDER CANCER -- Blood-based Biomarkers -- Tumor Cells -- CD8 Count and Immune Cells -- Matrix Metalloproteinase -- Epigenetic Markers -- Tissue-based Biomarkers -- Cell Cycle-based Markers -- Transmembrane- and Signaling-based Markers -- PDL/PDL1 -- mTOR -- MDR1 -- Human Epidermal Growth Factor Receptor 2 (HER2). Anaplastic Thyroid Cancer -- SEROLOGICAL BIOMARKERS -- Thyroglobulin -- Anti-thyroglobulin Antibodies -- Calcitonin and Procalcitonin -- Carcinoembryonic Antigen -- Other Peptides -- LIQUID BIOPSY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives -- Sinem Durmus1,*, Remise Gelisgen1 and Hafize Uzun2 -- INTRODUCTION -- DNA METHYLATION AND REGULATION MECHANISM -- DNA Methylation in Cancer -- Regional Hypermethylation -- Global Hypomethylation -- DNA Methylation Biomarkers in Cancer -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Tissue Based Biomarkers -- DNA Alterations: Polymorphisms -- Gene Expression -- MicroRNA (miRNA) -- Blood Based Biomarkers -- cfDNA and ctDNA -- cfmRNA and hTERT -- cfmiRNA -- CIRCULATING PROTEINS/PEPTIDES -- OTHER PREDICTIVE BIOMARKERS -- Thymidylate Synthase (TS) -- Epidermal Growth Factor Receptor (EGFR) -- Cyclooxygenase 2 (COX-2) -- Bax/bcl-2 -- P21 -- Ki-67 -- CEA -- ctDNA -- Circulating Tumour Cells (CTC) -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERANCES -- Circulating Biomarkers in the Management of Breast Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Carcinoembryonic Antigen (CEA) -- MUC-1 -- HER-2 -- Cytokeratins (CK) -- Specific Classes of Circulatory Biomarkers -- Proteins -- Autoantibodies -- Circulating Tumour Cells (CTC) -- Exosomes -- MicroRNA (miRNA) -- Circulating Cell-Free DNA (cfDNA). BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER -- MONITORING RESPONSE TO THERAPY AND SURVEILLANCE -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Biomarkers for Hematologic Malignancies -- Nurgül Özgür Yurttaş1 and Ahmet Emre Eşkazan1,* -- INTRODUCTION -- BIOMARKERS IN MYELOID NEOPLASMS -- Acute Myeloid Leukemia -- CYTOGENETIC CLASSIFICATION OF AML -- MRD IN AML -- Myelodysplastic Syndrome -- CHROMOSOMAL ABNORMALITIES IN MDS -- Deletions of Chromosome 5 -- Monosomy 7 and Deletions of Chromosome 7 -- Diagnosis and Classification -- 5q-syndrome/MDS with an Isolated del(5q) -- Role of Cytogenetics in the Prognosis of MDS -- GENETIC MUTATIONS IN MDS -- Myeloproliferative Neoplasms -- Mutations in PV, ET, and PMF -- BIOMARKERS IN CHRONIC MYELOID LEUKEMIA -- Prognostic Factors at the Time of Diagnosis -- Use of the Mutational Analysis in CML -- Identification of Molecular Markers of Progression -- BIOMARKERS IN LYMPHOID NEOPLASMS -- BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA -- CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA -- B-ALL/LBL with Recurrent Genetic Abnormalities -- T-ALL/LBL -- Cytogenetic Abnormalities in T-ALL/LBL -- Molecular Abnormalities in T-ALL/LBL -- EARLY T-CELL PRECURSOR ALL/LBL -- MRD IN ALL -- BIOMARKERS IN LYMPHOMAS -- Biomarkers of Genetic Changes -- B-Cell Lymphoma 6 (BCL6) -- Tumor Protein 53 (TP53) -- V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) -- B-Cell Lymphoma 2 (BCL2) -- Myeloid Differentiation Primary Response 88 (MYD88) -- Other Genetic Biomarkers in B-Cell Lymphomas -- Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL) -- Biomarkers Related to Epigenetic Changes -- Other Epigenetic Gene Features -- MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas. Other MicroRNAs and MicroRNA-Based Classifiers -- Immunophenotypic Biomarkers -- CD30 -- Bcl-6, Bcl-2, and Myc -- Cyclin D1 and SOX-11 -- TP53 and MDM2 -- Immunophenotypic Biomarkers -- Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma -- Microenvironment-related Biomarkers for Prognosis and Immunotherapy -- BIOMARKERS IN MULTIPLE MYELOMA -- STAGING SYSTEMS -- GENOMIC BIOMARKERS -- Gene Expression Profiling -- NOVEL BIOMARKERS -- Minimal Residual Disease -- Next-Generation Biomarkers in MM -- Immunotherapy-related Biomarkers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Applications of Biomarkers in Cancer Surgery -- Berrin Papila Kundaktepe1,* -- INTRODUCTION -- CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS -- Applications Of Tumor Markers In Colorectal Cancer -- Applications of Tumor Markers in Hepatocellular Carcinoma (HCC) -- Applications of Tumor Markers in Pancreatic Adenocarcinoma -- Applications of Tumor Markers In Breast Cancer -- Circulating Tumor Cells -- ENDOCRINE TUMOR MARKERS -- Immunohistochemical and Circulating Tumor Markers of NETs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- A Pathophysiological Approach To Current Biomarkers -- Aykut Oruc1,* and Gonul Simsek1 -- CARDIAC BIOMARKERS -- Cardiac Troponins -- Troponin Subunits -- Regulatory Function of Troponin -- Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology -- Cardiac Troponins as a Biomarker in Congestive Heart Failure -- Heart-Type Fatty Acid Binding Protein -- Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia -- Glycogen Phosphorylase Isoenzyme BB -- Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology -- Glutathione S-Transferase P1 -- N-Terminal pro-Brain Natriuretic Peptide. Biomarkers in Medicine is a comprehensive guide to understanding the current and future status of biomarkers. The book features 27 chapters focusing on disease biomarkers for diseases such as cancer, neurodegenerative diseases, cardiac diseases, metabolic conditions and much more. This book supplies readers with the unique insight of experts in multiple specialties in medicine and life sciences who have extensive experience in diagnostics and clinical laboratories. The book includes case studies and practical examples from different classes of biomarkers on different platforms, including new data for biomarkers in different therapeutic indications. In addition to presenting biomarker information, each chapter covers the relevant pathology and also emphasizes on preclinical and clinical manifestation of the disease process. Clinicians managing patients or clinical trials, clinical researchers, clinical laboratories, diagnostic companies, regulatory agencies, medical school graduate students, academic students, and the general public involved in healthcare delivery will all benefit from information presented in this book. Biomedical engineering. http://id.loc.gov/authorities/subjects/sh85014237 Radiology. http://id.loc.gov/authorities/subjects/sh85110774 Biochemical markers. http://id.loc.gov/authorities/subjects/sh85014122 Tumor markers. http://id.loc.gov/authorities/subjects/sh85138551 Biomarkers https://id.nlm.nih.gov/mesh/D015415 Biomarkers, Tumor https://id.nlm.nih.gov/mesh/D014408 Radiology https://id.nlm.nih.gov/mesh/D011871 Génie biomédical. Radiologie. Marqueurs biologiques. Marqueurs tumoraux. biomedical engineering. aat radiology. aat Biochemical Markers Clinical Biochemistry Science Medical FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3378745 Volltext |
| spellingShingle | PINAR, ATUKEREN; HAFIZE, UZUN BIOMARKERS IN MEDICINE Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- New Biomarkers and Immunotherapy Decision -- Abdurrahman Yigit1, Berkay Kuscu2, Ali Kirik2, Ruhsen Ozcaglayan2 and Cigdem Usul Afsar3,* -- NEW BIOMARKERS AND IMMUNOTHERAPY DECISION -- Principles of Cancer İmmunotherapy -- Tumor Immunology -- Therapeutic Approaches -- Immune Checkpoint Inhibitors (ICI) -- THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY -- Immunotherapy Toxicity -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Gynecologic Tumors -- Selim Afsar1,* -- INTRODUCTION -- Ovarian and Fallopian Tube Cancers -- Carbohydrate Antigen 125 (CA125) -- Screening -- Prediction Models -- Prognosis -- Recurrence -- Human Epididymis Protein 4 (HE4) -- Diagnosis -- Prognosis -- Risk of Ovarian Malignancy Algorithm (ROMA) -- Circulating Cell-Free DNA (cfDNA) -- DNA Methylation -- Metabolites -- MicroRNAs -- Carcinoembryonic Antigen (CEA) -- Alpha-Fetoprotein (AFP) -- Inhibin B -- Human Chorionic Gonadotropin (hCG) -- Kallikreins -- Other Markers -- Uterine Cancer -- CA125 -- HE4 -- Genomic Classification -- Other Markers -- Cervical Cancer -- Squamous Cell Carcinoma Antigen (SCC-Ag) -- Other Markers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Urological Cancers -- Bulent Onal1,*, Mehmet Hamza Gultekin1, Muhammed Fatih Simsekoglu1, Berin Selcuk1 and Ahmet Gurbuz1 -- BIOMARKERS IN BLADDER CANCER -- Blood-based Biomarkers -- Tumor Cells -- CD8 Count and Immune Cells -- Matrix Metalloproteinase -- Epigenetic Markers -- Tissue-based Biomarkers -- Cell Cycle-based Markers -- Transmembrane- and Signaling-based Markers -- PDL/PDL1 -- mTOR -- MDR1 -- Human Epidermal Growth Factor Receptor 2 (HER2). Anaplastic Thyroid Cancer -- SEROLOGICAL BIOMARKERS -- Thyroglobulin -- Anti-thyroglobulin Antibodies -- Calcitonin and Procalcitonin -- Carcinoembryonic Antigen -- Other Peptides -- LIQUID BIOPSY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives -- Sinem Durmus1,*, Remise Gelisgen1 and Hafize Uzun2 -- INTRODUCTION -- DNA METHYLATION AND REGULATION MECHANISM -- DNA Methylation in Cancer -- Regional Hypermethylation -- Global Hypomethylation -- DNA Methylation Biomarkers in Cancer -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Tissue Based Biomarkers -- DNA Alterations: Polymorphisms -- Gene Expression -- MicroRNA (miRNA) -- Blood Based Biomarkers -- cfDNA and ctDNA -- cfmRNA and hTERT -- cfmiRNA -- CIRCULATING PROTEINS/PEPTIDES -- OTHER PREDICTIVE BIOMARKERS -- Thymidylate Synthase (TS) -- Epidermal Growth Factor Receptor (EGFR) -- Cyclooxygenase 2 (COX-2) -- Bax/bcl-2 -- P21 -- Ki-67 -- CEA -- ctDNA -- Circulating Tumour Cells (CTC) -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERANCES -- Circulating Biomarkers in the Management of Breast Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Carcinoembryonic Antigen (CEA) -- MUC-1 -- HER-2 -- Cytokeratins (CK) -- Specific Classes of Circulatory Biomarkers -- Proteins -- Autoantibodies -- Circulating Tumour Cells (CTC) -- Exosomes -- MicroRNA (miRNA) -- Circulating Cell-Free DNA (cfDNA). BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER -- MONITORING RESPONSE TO THERAPY AND SURVEILLANCE -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Biomarkers for Hematologic Malignancies -- Nurgül Özgür Yurttaş1 and Ahmet Emre Eşkazan1,* -- INTRODUCTION -- BIOMARKERS IN MYELOID NEOPLASMS -- Acute Myeloid Leukemia -- CYTOGENETIC CLASSIFICATION OF AML -- MRD IN AML -- Myelodysplastic Syndrome -- CHROMOSOMAL ABNORMALITIES IN MDS -- Deletions of Chromosome 5 -- Monosomy 7 and Deletions of Chromosome 7 -- Diagnosis and Classification -- 5q-syndrome/MDS with an Isolated del(5q) -- Role of Cytogenetics in the Prognosis of MDS -- GENETIC MUTATIONS IN MDS -- Myeloproliferative Neoplasms -- Mutations in PV, ET, and PMF -- BIOMARKERS IN CHRONIC MYELOID LEUKEMIA -- Prognostic Factors at the Time of Diagnosis -- Use of the Mutational Analysis in CML -- Identification of Molecular Markers of Progression -- BIOMARKERS IN LYMPHOID NEOPLASMS -- BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA -- CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA -- B-ALL/LBL with Recurrent Genetic Abnormalities -- T-ALL/LBL -- Cytogenetic Abnormalities in T-ALL/LBL -- Molecular Abnormalities in T-ALL/LBL -- EARLY T-CELL PRECURSOR ALL/LBL -- MRD IN ALL -- BIOMARKERS IN LYMPHOMAS -- Biomarkers of Genetic Changes -- B-Cell Lymphoma 6 (BCL6) -- Tumor Protein 53 (TP53) -- V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) -- B-Cell Lymphoma 2 (BCL2) -- Myeloid Differentiation Primary Response 88 (MYD88) -- Other Genetic Biomarkers in B-Cell Lymphomas -- Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL) -- Biomarkers Related to Epigenetic Changes -- Other Epigenetic Gene Features -- MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas. Other MicroRNAs and MicroRNA-Based Classifiers -- Immunophenotypic Biomarkers -- CD30 -- Bcl-6, Bcl-2, and Myc -- Cyclin D1 and SOX-11 -- TP53 and MDM2 -- Immunophenotypic Biomarkers -- Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma -- Microenvironment-related Biomarkers for Prognosis and Immunotherapy -- BIOMARKERS IN MULTIPLE MYELOMA -- STAGING SYSTEMS -- GENOMIC BIOMARKERS -- Gene Expression Profiling -- NOVEL BIOMARKERS -- Minimal Residual Disease -- Next-Generation Biomarkers in MM -- Immunotherapy-related Biomarkers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Applications of Biomarkers in Cancer Surgery -- Berrin Papila Kundaktepe1,* -- INTRODUCTION -- CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS -- Applications Of Tumor Markers In Colorectal Cancer -- Applications of Tumor Markers in Hepatocellular Carcinoma (HCC) -- Applications of Tumor Markers in Pancreatic Adenocarcinoma -- Applications of Tumor Markers In Breast Cancer -- Circulating Tumor Cells -- ENDOCRINE TUMOR MARKERS -- Immunohistochemical and Circulating Tumor Markers of NETs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- A Pathophysiological Approach To Current Biomarkers -- Aykut Oruc1,* and Gonul Simsek1 -- CARDIAC BIOMARKERS -- Cardiac Troponins -- Troponin Subunits -- Regulatory Function of Troponin -- Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology -- Cardiac Troponins as a Biomarker in Congestive Heart Failure -- Heart-Type Fatty Acid Binding Protein -- Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia -- Glycogen Phosphorylase Isoenzyme BB -- Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology -- Glutathione S-Transferase P1 -- N-Terminal pro-Brain Natriuretic Peptide. Biomedical engineering. http://id.loc.gov/authorities/subjects/sh85014237 Radiology. http://id.loc.gov/authorities/subjects/sh85110774 Biochemical markers. http://id.loc.gov/authorities/subjects/sh85014122 Tumor markers. http://id.loc.gov/authorities/subjects/sh85138551 Biomarkers https://id.nlm.nih.gov/mesh/D015415 Biomarkers, Tumor https://id.nlm.nih.gov/mesh/D014408 Radiology https://id.nlm.nih.gov/mesh/D011871 Génie biomédical. Radiologie. Marqueurs biologiques. Marqueurs tumoraux. biomedical engineering. aat radiology. aat |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85014237 http://id.loc.gov/authorities/subjects/sh85110774 http://id.loc.gov/authorities/subjects/sh85014122 http://id.loc.gov/authorities/subjects/sh85138551 https://id.nlm.nih.gov/mesh/D015415 https://id.nlm.nih.gov/mesh/D014408 https://id.nlm.nih.gov/mesh/D011871 |
| title | BIOMARKERS IN MEDICINE |
| title_auth | BIOMARKERS IN MEDICINE |
| title_exact_search | BIOMARKERS IN MEDICINE |
| title_full | BIOMARKERS IN MEDICINE [electronic resource]. |
| title_fullStr | BIOMARKERS IN MEDICINE [electronic resource]. |
| title_full_unstemmed | BIOMARKERS IN MEDICINE [electronic resource]. |
| title_short | BIOMARKERS IN MEDICINE |
| title_sort | biomarkers in medicine |
| topic | Biomedical engineering. http://id.loc.gov/authorities/subjects/sh85014237 Radiology. http://id.loc.gov/authorities/subjects/sh85110774 Biochemical markers. http://id.loc.gov/authorities/subjects/sh85014122 Tumor markers. http://id.loc.gov/authorities/subjects/sh85138551 Biomarkers https://id.nlm.nih.gov/mesh/D015415 Biomarkers, Tumor https://id.nlm.nih.gov/mesh/D014408 Radiology https://id.nlm.nih.gov/mesh/D011871 Génie biomédical. Radiologie. Marqueurs biologiques. Marqueurs tumoraux. biomedical engineering. aat radiology. aat |
| topic_facet | Biomedical engineering. Radiology. Biochemical markers. Tumor markers. Biomarkers Biomarkers, Tumor Radiology Génie biomédical. Radiologie. Marqueurs biologiques. Marqueurs tumoraux. biomedical engineering. radiology. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3378745 |
| work_keys_str_mv | AT pinaratukerenhafizeuzun biomarkersinmedicine |